Cytosorbents Q3 2025 earnings show a mixed quarter, beating EPS estimates but missing on revenue. The stock saw volatility despite a strengthened balance sheet.
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
CytoSorbents (CTSO) reported Q2 2025 results with revenue of $9.62M, beating estimates, and a narrower EPS loss of -$0.05. Shares rose 4.32% post-earnings amid steady demand for CytoSorb.
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
